DK2298314T3 - Dosage unit comprising a prostaglandin analog for the treatment of constipation - Google Patents

Dosage unit comprising a prostaglandin analog for the treatment of constipation Download PDF

Info

Publication number
DK2298314T3
DK2298314T3 DK10010211.0T DK10010211T DK2298314T3 DK 2298314 T3 DK2298314 T3 DK 2298314T3 DK 10010211 T DK10010211 T DK 10010211T DK 2298314 T3 DK2298314 T3 DK 2298314T3
Authority
DK
Denmark
Prior art keywords
dosage unit
analog
dose
constipation
formula
Prior art date
Application number
DK10010211.0T
Other languages
Danish (da)
English (en)
Inventor
Ryuji Ueno
Myra L Patchen
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23293447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2298314(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Application granted granted Critical
Publication of DK2298314T3 publication Critical patent/DK2298314T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/23—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen containing rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
DK10010211.0T 2001-11-14 2002-11-14 Dosage unit comprising a prostaglandin analog for the treatment of constipation DK2298314T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33131601P 2001-11-14 2001-11-14
EP02780083A EP1443938B1 (en) 2001-11-14 2002-11-14 Dosage unit comprising a prostaglandin analog for treating constipation

Publications (1)

Publication Number Publication Date
DK2298314T3 true DK2298314T3 (en) 2014-12-01

Family

ID=23293447

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10010211.0T DK2298314T3 (en) 2001-11-14 2002-11-14 Dosage unit comprising a prostaglandin analog for the treatment of constipation
DK02780083.8T DK1443938T3 (da) 2001-11-14 2002-11-14 Dosisenhed omfattende en prostaglantinanalog til behandling af forstoppelse

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK02780083.8T DK1443938T3 (da) 2001-11-14 2002-11-14 Dosisenhed omfattende en prostaglantinanalog til behandling af forstoppelse

Country Status (14)

Country Link
US (3) US8097653B2 (enExample)
EP (2) EP1443938B1 (enExample)
JP (2) JP4852229B2 (enExample)
AR (3) AR037524A1 (enExample)
AT (1) ATE522218T1 (enExample)
BR (1) BR0214075A (enExample)
CA (1) CA2464420C (enExample)
CY (1) CY1115856T1 (enExample)
DK (2) DK2298314T3 (enExample)
ES (2) ES2524369T3 (enExample)
LU (1) LU92826I2 (enExample)
PT (2) PT2298314E (enExample)
TW (1) TWI331920B (enExample)
WO (1) WO2003041716A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI331920B (en) * 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
US8114911B2 (en) * 2002-10-23 2012-02-14 Sucampo Ag Prostaglandin compounds for the treatment of obesity
ES2591252T3 (es) * 2002-12-27 2016-11-25 Sucampo Ag Derivados de prostaglandinas para tratar el síndrome de colon irritable y/o la dispepsia funcional
JP5294559B2 (ja) * 2003-07-03 2013-09-18 スキャンポ・アーゲー クロライドチャンネルオープナーとしてプロスタグランジンアナログを含む腸溶性組成物
TWI387454B (zh) * 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CN101171010B (zh) * 2005-03-07 2014-09-17 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
KR20140069182A (ko) * 2005-04-12 2014-06-09 수캄포 아게 위장 장애 치료를 위한 프로스타글란딘 화합물과 양성자 펌프 억제제의 병용
PT1978944E (pt) * 2006-01-24 2012-11-26 Sucampo Ag Formulação em cápsula de gelatina mole
KR20140147142A (ko) * 2006-01-24 2014-12-29 가부시키가이샤 아루떼꾸 우에노 바이-사이클릭 화합물을 함유하는 약학적 조성물 및 바이-사이클릭 화합물의 안정화 방법
US20090030072A1 (en) * 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
US20090012165A1 (en) * 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
KR20120092592A (ko) * 2009-09-18 2012-08-21 아돌로 코포레이션 위장관 질환을 위한 오피오이드 수용체 길항제의 용도
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5350141A (en) 1976-10-18 1978-05-08 Ono Pharmaceut Co Ltd Stabilization of prostaglandin and prostaglandin analogues
GB1581886A (en) 1977-05-26 1980-12-31 May & Baker Ltd Prostanol derivatives
JPH0681728B2 (ja) 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
ES2051862T3 (es) * 1987-10-02 1994-07-01 Ueno Seiyaku Oyo Kenkyujo Kk Un metodo para producir un medicamento que tiene un efecto catartico.
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
CA2027814C (en) * 1989-10-20 1996-07-30 Ryuji Ueno Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
CA2030346C (en) * 1989-11-22 2000-04-11 Ryuji Ueno Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
CA2030344C (en) 1989-11-22 2000-04-18 Ryuji Ueno Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
CA2030345C (en) * 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
CA2041417C (en) * 1990-05-01 2002-05-21 Ryuji Ueno Treatment of pancreatic disease with 15-keto-prostaglandin compounds
CA2046069C (en) * 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
JP2938579B2 (ja) 1990-12-15 1999-08-23 株式会社上野製薬応用研究所 消化管壁保護剤
DK0503887T3 (da) * 1991-03-14 1996-09-16 R Tech Ueno Ltd Fremme af sårheling med 15-ketoprostaglandinforbindelser
ATE169015T1 (de) * 1992-02-04 1998-08-15 Eisai Co Ltd Aminobenzoesäure derivate
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
JP3183615B2 (ja) * 1994-06-03 2001-07-09 株式会社アールテック・ウエノ 肝・胆道系疾患処置剤
WO1997047595A1 (en) * 1996-06-10 1997-12-18 R-Tech Ueno, Ltd. Endothelin antagonist
DE19717005A1 (de) * 1997-04-23 1998-10-29 Kennametal Inc Spannfutter für Rundlaufwerkzeuge
PT978284E (pt) * 1997-11-28 2008-10-07 Sucampo Ag Utilização de compostos 15-ceto-prostaglandina-e como antagonistas da endotelina
US6492417B1 (en) 1997-12-22 2002-12-10 Alcon Manufacturing, Ltd. 11-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonists
ATE402925T2 (de) * 1999-10-15 2008-08-15 Sucampo Ag Neue zusammensetzung enthaltend eine bicyclische verbindung und ein glycerid
ATE433754T1 (de) 2000-04-06 2009-07-15 Sucampo Ag Gallensäurefördernde zusammensetzung für lebertransplantation welche ein 15-keto prostaglandin enthält
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
ATE387204T1 (de) 2001-05-18 2008-03-15 Sucampo Ag Zusammensetzung mit induzierendem kathartischen effekt
CA2458471C (en) * 2001-08-31 2012-07-31 Sucampo Ag Prostaglandin analogs as chloride channel opener
TWI331920B (en) 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
TWI263505B (en) 2001-11-19 2006-10-11 Sucampo Ag Pharmaceutical composition comprising a C1C-2 channel opener
ES2591252T3 (es) * 2002-12-27 2016-11-25 Sucampo Ag Derivados de prostaglandinas para tratar el síndrome de colon irritable y/o la dispepsia funcional

Also Published As

Publication number Publication date
BR0214075A (pt) 2004-09-28
TW200300091A (en) 2003-05-16
WO2003041716A1 (en) 2003-05-22
DK1443938T3 (da) 2011-09-26
US8389542B2 (en) 2013-03-05
CA2464420C (en) 2011-12-13
US8097653B2 (en) 2012-01-17
EP2298314B1 (en) 2014-09-03
US20030119898A1 (en) 2003-06-26
LU92826I2 (fr) 2015-11-24
CA2464420A1 (en) 2003-05-22
EP1443938A1 (en) 2004-08-11
AR117404A2 (es) 2021-08-04
ES2524369T3 (es) 2014-12-05
PT2298314E (pt) 2014-12-03
JP4852229B2 (ja) 2012-01-11
ATE522218T1 (de) 2011-09-15
US20120088824A1 (en) 2012-04-12
EP2298314A1 (en) 2011-03-23
US20130143958A1 (en) 2013-06-06
JP2011201905A (ja) 2011-10-13
JP2005513014A (ja) 2005-05-12
AR098997A2 (es) 2016-06-22
PT1443938E (pt) 2011-09-27
ES2368729T3 (es) 2011-11-21
TWI331920B (en) 2010-10-21
AR037524A1 (es) 2004-11-17
EP1443938B1 (en) 2011-08-31
CY1115856T1 (el) 2017-01-25
HK1155649A1 (en) 2012-05-25

Similar Documents

Publication Publication Date Title
US8389542B2 (en) Dosage unit comprising a prostaglandin analog for treating constipation
EP1315485B1 (en) Cathartic composition
CA2444103C (en) Composition for treating drug-induced constipation with 15-keto-prostaglandins
US20140315994A1 (en) Method for treating gastrointestinal disorder
HK1155649B (en) Dosage unit comprising a prostaglandin analog for treating constipation
KR20000068996A (ko) 자궁 경관 숙화제
DE69019431T2 (de) Verwendung von 15-Keto-Prostansäure-Derivaten zur Herstellung eines Medikaments für die Verbesserung der Ausscheidung des Kaliumions.
RU2392941C2 (ru) Производные простагландинов для лечения желудочно-кишечного нарушения